Evidence map›Paper›PMID 36050251›Full record

ArticleNeuromuscular disorders : NMD2022

Correlations of disease severity outcome measures in inclusion body myositis.

Namita A Goyal, Steven A Greenberg, Jonathan Cauchi, Nadia Araujo, Vivian Li, Marie Wencel, Tyler Irani, Leo H Wang, Anton M Palma, S Armando Villalta and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuromuscular disorders : NMD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Namita A GoyalDepartment of Neurology, University of California, Irvine, CA, United States. Electronic address: namitag@hs.uci.edu.
Steven A GreenbergDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Jonathan CauchiDepartment of Neurology, University of California, Irvine, CA, United States.
Nadia AraujoDepartment of Neurology, University of California, Irvine, CA, United States.
Vivian LiDepartment of Neurology, University of California, Irvine, CA, United States.
Marie WencelDepartment of Neurology, University of California, Irvine, CA, United States.
Tyler IraniDepartment of Neurology, University of California, Irvine, CA, United States.
Leo H WangDepartment of Neurology, University of Washington Medical Center, Seattle, WA, United States.
Anton M PalmaInstitute for Clinical and Translational Science, University of California, Irvine, CA, United States.
S Armando VillaltaDepartment of Neurology, University of California, Irvine, CA, United States; Institute for Immunology, United States; Department of Physiology and Biophysics, United States.
Tahseen MozaffarDepartment of Neurology, University of California, Irvine, CA, United States; Institute for Immunology, United States; Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, United States.

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Institutional Career Development CoreKL2TR001416 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, DEMETRIOU, MICHAEL · 2015 to 2023
$5.6M
Influence of NT5c1A antibodies on disease progression, clinical phenotype and blood and muscle biomarkers in sporadic Inclusion Body Myositis - A prospective evaluationR01AR078340 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI MOZAFFAR, TAHSEEN · 2021 to 2025
$4.2M
Novel macrophage and regulatory T cell interactions that promote the pathogenesis of Duchenne muscular dystrophyR01NS120060 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALTA, SERGIO ARMANDO · 2020 to 2024
$2.5M
UCI-NEXT, a NeuroNEXT siteU24NS107210 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI MOZAFFAR, TAHSEEN · 2018 to 2022
$1.5M
Tolerization of dystrophin and adeno-associated virus immunityR21NS114918 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALTA, SERGIO ARMANDO · 2020 to 2020
$431k
NCATS NIH HHS KL2 TR001416NCATS NIH HHS UL1 TR001414NIAMS NIH HHS R01 AR078340NINDS NIH HHS R01 NS120060NINDS NIH HHS R21 NS114918NINDS NIH HHS U24 NS107210
6 · The paper itself

Abstract

This study aimed to evaluate the correlation between various outcome measures used to assess disease severity and progression in inclusion body myositis (IBM) clinical trials. A cross-sectional study, involving 51 IBM patients meeting the European Neuromuscular Center (ENMC) 2011 criteria for clinically defined or probable IBM, was completed at the University of California, Irvine. Clinical details, demographic data, and functional data including timed get up (TGU), manual muscle testing, hand grip, pinch dynamometry, as well as IBM functional rating scale (IBMFRS), modified Rankin score, forced vital capacity (FVC), and modified ocular bulbar facial respiratory scale (mOBFRS) were collected on all patients. Descriptive statistics and Pearson's r correlation were performed to analyze the data. Age of the patient did not correlate with any of the outcome measures. Greater severity of IBMFRS scores correlated with longer disease duration as well as greater severity for FVC, strength outcomes, TGU, modified Rankin, and mOBFRS. Additionally, TGU strongly correlated with muscle strength measurements, modified Rankin, and mOBFRS. mOBFRS moderately correlated with IBMFRS, muscle strength, FVC, TGU and modified Rankin score. We demonstrate moderate to strong correlations among the disease severity outcome measures in this study.

Indexed as

Myositis, Inclusion BodyCross-Sectional StudiesHand StrengthHumansOutcome Assessment, Health CareSeverity of Illness IndexClinical trialsIBMFRSInclusion body myositisOutcome measures

Identifiers

PMID36050251
PMCPMC10069380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.